The Syntopix Group has announced a joint development agreement with Procter & Gamble to investigate the use of Syntopix’s novel antimicrobial technology to improve efficacy of a Proctor & Gamble consumer healthcare brand.
This latest agreement emphasises Syntopix’s strategy of leveraging its compound library and intellectual assets into markets outside of dermatological disease and into broader consumer healthcare markets. Procter & Gamble will also have the opportunity to commercialise the technology being developed.
Syntopix’s chief executive officer Dr Stephen Jones said: ‘We believe that Syntopix’s antimicrobial technology has the potential to improve the effectiveness of consumer healthcare brands and it is particularly pleasing to sign this agreement with a company such as Procter & Gamble.’
He added: ‘This agreement validates our strategy of broadening the number of potential markets available to the antimicrobial expertise of Syntopix to include consumer healthcare, as well as the over the counter and prescription markets associated with treating dermatological conditions.’